Publications

2019

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, et al. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019;35(4):603-617.e8.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10(1):2977.
Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, et al. Clinicopathologic and genetic characterization of nonacute -mutated myeloid neoplasms. Blood Adv. 2019;3(9):1540-1545.
Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.
Kobayashi S, Contractor T, Vosburgh E, Du Y-, Tang LH, Clausen R, et al. Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis. 2019;8(3):16.
Eichenberger EM, Soave R, Zappetti D, Small CB, Shore T, Van Besien K, et al. Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019;54(7):1058-1066.
Chen B-, Quinet A, Byrum AK, Jackson J, Berti M, Thangavel S, et al. XLF and H2AX function in series to promote replication fork stability. J Cell Biol. 2019;218(7):2113-2123.
Zadra G, Loda M. When fat goes down, prostate cancer is on the ropes. Mol Cell Oncol. 2019;6(3):1595308.
Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166-173.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700